1. Search Result
Search Result
Results for "

NMDA-IN-2

" in MedChemExpress (MCE) Product Catalog:

7

Inhibitors & Agonists

2

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-14777

    RGH-896

    iGluR Neurological Disease
    Radiprodil (RGH-896) is an orally active and selective NMDA NR2B antagonist. A potential therapeutic agent in treatment of neuropathic pain and possibly other chronic pain conditions .
    Radiprodil
  • HY-121100

    iGluR Neurological Disease
    BZAD-01 is a potent, selective and orally active inhibitor of NMDA NR2B subunit, with a Ki of 72 nM. BZAD-01 can improve postural asymmetry as well as Apomorphine-induced rotation .
    BZAD-01
  • HY-145897

    iGluR Neurological Disease
    NMDA-IN-2 (compound 6b), a Procaine derivative, is a NMDA receptor 2B subtype inhibitor .
    NMDA-IN-2
  • HY-172121

    iGluR Neurological Disease
    NMDA agonist 2 (compound 8d) is a potent inhibitor of NMDA receptor, with the EC50 of 0.034 μM for GluN1/2C. NMDA agonist 2 plays an important role in neurological and psychiatric disorders .
    NMDA agonist 2
  • HY-B0184S1

    Felbamyl-d5; Felbatol-d5; Taloxa-d5

    iGluR Neurological Disease
    Felbamate-d5 is the deuterium labeled Felbamate[1]. Felbamate (W-554) is a potent nonsedative anticonvulsant whose clinical effect may be related to the inhibition of N-methyl-D-aspartate (NMDA)[2][3].
    Felbamate-d5
  • HY-Y0966S11

    iGluR Endogenous Metabolite Neurological Disease
    Glycine- 13C2, 15N,d2 is the deuterium, 13C and 15N labeled Glycine[1]. Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors[2].
    Glycine-13C2,15N,d2
  • HY-161211

    17β-HSD iGluR Metabolic Disease
    HSD17B13-IN-7 (compound 1), a fluorophenol-containing compound, is a potent HSD17B13 inhibitor with IC50s of 0.18 μM and 0.25 μM β-estradiol and Leukotriene B4 as substrates, respectively. HSD17B13-IN-7 is a potent N-methyl-D-aspartate (NMDA) NR2B receptor antagonist. HSD17B13-IN-7 has the potential for non-alcoholic fatty liver disease research .
    HSD17B13-IN-7